ABBV-1042 / AbbVie - LARVOL DELTA

A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: AbbVie | Trial primary completion date: May 2026 ➔ Sep 2026 | Recruiting ➔ Active, not recruiting | Trial completion date: May 2026 ➔ Sep 2026

Adverse events • Enrollment closed • First-in-human • Trial completion date • Trial primary completion date